Potential risk of neoplasms with fezolinetant: clinical evidence, mechanisms, and post-marketing implications

Journal of the Endocrine Society · Published 2026-04-01 · DOI 10.1210/jendso/bvag082

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1210/jendso/bvag082

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Related articles